A major population proteomics study using UK Biobank patient samples backed by 14 pharma companies has launched today with ...

Through a series of position papers, the EFPIA representing brandname drugmakers, self-medication group organisation AESGP, ...

The stake comes alongside an agreement for Vancouver, Washington-based Absci to use AMD chips and software to power its drug ...

Investor interest in companies with obesity candidates in their pipeline clearly remains high, given that a brand new ...

In pharmaphorum’s inaugural Life Sciences Industry Report 2025, delve into the trends that propelled the pharmaceutical ...

According to the paper by researchers at the University of Bath in the UK and Lund University in Sweden, the self-regulated ...

Bioanalysis is also used to monitor therapeutic responses by evaluating drug levels, biomarkers, and physiological changes ...

In conclusion, I see 2025 as a year in which the patient will still be centre-stage. But, in order for that to happen ...

In a statement, Neumora revealed that the KOASTAL-1 study missed its primary endpoint, with navacaprant failing to achieve a ...

In a deal valued at up to $1 billion, Roche has licensed rights to a DLL3-directed antibody-drug conjugate (ADC) from China's ...

Now, Novartis hopes to be able to share the data with regulatory authorities in 2025, including the US FDA, in the hope of ...

The JV was set up in 2001 and has become increasingly peripheral to Hutchmed's core business of developing novel therapies ...